Background/Objectives: Specialized pro-resolving lipid mediators (SPMs), such as Resolvin E1 (RvE1) and Resolvin D1 (RvD1), play a critical role in the resolution phase of inflammation. However, their relevance to tendon pathology and tissue-specific degeneration in rotator cuff tears remains unclear. This study aimed to investigate the relation between serum RvE1 and RvD1 levels and the morphological severity of tendon retraction and muscle fatty degeneration in patients with full-thickness rotator cuff tears. Methods: A total of 70 participants were included: 35 patients with full-thickness rotator cuff tears determined by magnetic resonance imaging (MRI) and 35 healthy controls. Tendon retraction and muscle fatty degeneration were graded using Patte and Goutallier classifications, respectively. Serum RvE1 and RvD1 levels were measured using enzyme-linked immunosorbent assay (ELISA). Group comparisons were performed using Welch’s t-test, and correlations were analyzed with Spearman’s coefficient. Results: RvE1 and RvD1 levels were significantly lower in patients compared to controls (p < 0.001). RvE1 showed a moderate positive correlation with Patte score (ρ = 0.37, p = 0.027), while no significant correlation was observed with Goutallier classification (ρ = 0.19, p = 0.27). RvD1 levels demonstrated no significant relationship with either morphological parameter. Conclusions: These findings suggest that decreased serum RvE1 levels are associated with the severity of tendon retraction but not with muscle fatty degeneration. Therefore, RvE1 may serve as a potential biochemical biomarker reflecting tendon damage severity and the impaired resolution of inflammation in rotator cuff tears.

Objective: In the present study, cardiovascular risk indices (Atherogenic Index of Plasma [AIP], Atherogenic Coefficient [AC], Castelli Risk Index-1 [CRI-1], and Castelli Risk Index-2 [CRI-2]) and bone mineral density (BMD SDS) were evaluated in patients with Familial Mediterranean Fever (FMF), and the association of these parameters with disease severity and MEFV gene mutations was investigated. Methods: A total of 126 participants (96 FMF patients and 30 healthy controls) were included in the study. FMF patients were classified as mild, moderate, or severe according to the PRAS severity score. Cardiovascular risk indices, biochemical parameters of bone metabolism, and BMD SDS values were compared among the groups. The relationship between BMD SDS and atherogenic indices was assessed by Spearman correlation analysis. The results were also analyzed according to MEFV gene mutations. Results: No significant difference was detected among the groups in terms of sex or age (p>0.05). FMF patients were found to have substantially higher cardiovascular risk indices than the control group, and these indices increased in parallel with disease severity (p< 0.05). The BMD SDS value of the severe FMF group was significantly lower than that of the other groups (p=0.025). No difference was detected among the groups with respect to bone metabolism parameters (p>0.05). No significant correlation was observed between BMD SDS and cardiovascular risk indices (p>0.05). M694V was the most frequently detected mutation, and the BMD SDS value was lower in patients carrying mutations other than M694V (p=0.011). Conclusion: The increased cardiovascular risk in FMF patients is associated with disease severity. Severe disease is accompanied by a reduction in bone mineral density. The lack of an association between cardiovascular risk and bone mineral density suggests that these systems may be affected through different mechanisms. It is important that FMF patients be monitored with respect to cardiovascular and bone health.

Aim: This current research aims to determine the predictive value of the ratio of triglyceride (TG)/high-density lipoprotein cholesterol (HDL-C), index of triglyceride–glucose (TyG), homeostatic model assessment for insulin resistance (HOMA-IR) score, and anthropometric measurements at the onset of non-alcoholic fatty liver disease (NAFLD) in obese kids and juveniles. It also sought to assess how novel cardiovascular risk markers are affected in obese pediatric patients with NAFLD. Materials and Methods: Between November 2024 and May 2025, a total of 199 pediatric patients were prospectively evaluated, including 150 children with obesity and 49 entirely healthy controls. Two categories of obese patients were created based on whether or not they had non-alcoholic fatty liver disease. These groups were compared with each other and with the control group in terms of HOMA-IR score, index of TyG, ratio of TG/HDL-C, anthropometric parameters (percentage of body fat [BFP], index of body mass [BMI], body fat mass [BFM], waist circumference [WC]), and cardiovascular risk markers. The cutoff values, sensitivity, and specificity of the HOMA-IR score, ratio of TG/HDL-C, anthropometric measurements, and index of TyG in predicting NAFLD were assessed using Receiver Operating Characteristic (ROC) analysis. Results: Obese kids and juveniles with NAFLD had significantly higher TG/HDL-C ratios, TyG indices, HOMA-IR scores, anthropometric measurements, and cardiovascular risk markers than those without NAFLD (p < 0.001). The TG/HDL-C ratio (AUC: 0.936; 81.8% sensitivity, 95.9% specificity) and the TyG index (AUC: 0.912; 81.8% sensitivity, 91.8% specificity) showed strong predictive value for NAFLD, while HOMA-IR and WC were found to be relatively weaker predictors. Conclusions: The index of TyG and ratio of TG/HDL-C are highly effective parameters in predicting NAFLD development in obese kids and juveniles. Those with increased WC and BFP should be closely monitored for NAFLD development. Pediatric patients with NAFLD should be carefully followed up for potential cardiovascular diseases.

Objective: Transient tachypnea of the newborn (TTN) is a common condition observed in neonates. Since its management often requires intensive care and leads to maternal–infant separation, it is a major source of parental concern. The present study aimed to evaluate the effects of lipoxin A4 and resolvin D1 on the clinical course of TTN and to determine whether complete blood count parameters could serve as predictors of disease severity. Materials and Methods: A total of 62 neonates admitted to the neonatal intensive care unit with a diagnosis of TTN were included. According to Silverman scoring, infants were divided into a mild group (n = 31) and a severe group (n = 31). Lipoxin A4 and resolvin D1 levels, together with complete blood count parameters, were compared between the two groups. Logistic regression and receiver operating characteristic (ROC) curve analyses were performed to assess the predictive value of these parameters for the clinical course. Results: Serum lipoxin A4 (p = 0.005) and resolvin D1 (p = 0.002) levels were significantly higher in the mild group compared with the severe group, whereas the neutrophil-to-lymphocyte ratio (p = 0.044) and platelet-to-lymphocyte ratio (p = 0.027) were significantly lower. Resolvin D1 and the platelet-to-lymphocyte ratio were identified as significant predictors of severe disease. In predicting a mild course, lipoxin A4 demonstrated the highest sensitivity (80.6%), while resolvin D1 exhibited the highest specificity (87.1%). Conclusions: Lipoxin A4 and resolvin D1 appear to play a protective role in preventing severe clinical progression of transient tachypnea of the newborn.

In the present study, cardiovascular risk indices (Atherogenic Index of Plasma [AIP], Atherogenic Coefficient [AC], Castelli Risk Index-1 [CRI-1], and Castelli Risk Index-2 [CRI-2]) and bone mineral density (BMD SDS) were evaluated in patients with Familial Mediterranean Fever (FMF), and the association of these parameters with disease severity and MEFV gene mutations was investigated. A total of 126 participants (96 FMF patients and 30 healthy controls) were included in the study. FMF patients were classified as mild, moderate, or severe according to the PRAS severity score. Cardiovascular risk indices, biochemical parameters of bone metabolism, and BMD SDS values were compared among the groups. The relationship between BMD SDS and atherogenic indices was assessed by Spearman correlation analysis. The results were also analyzed according to MEFV gene mutations. No significant difference was detected among the groups in terms of sex or age (p > 0.05). FMF patients were found to have substantially higher cardiovascular risk indices than the control group, and these indices increased in parallel with disease severity (p < 0.05). The BMD SDS value of the severe FMF group was significantly lower than that of the other groups (p = 0.025). No difference was detected among the groups with respect to bone metabolism parameters (p > 0.05). No significant correlation was observed between BMD SDS and cardiovascular risk indices (p > 0.05). M694V was the most frequently detected mutation, and the BMD SDS value was lower in patients carrying mutations other than M694V (p = 0.011). The increased cardiovascular risk in FMF patients is associated with disease severity. Severe disease is accompanied by a reduction in bone mineral density. The lack of an association between cardiovascular risk and bone mineral density suggests that these systems may be affected through different mechanisms. It is important that FMF patients are monitored with respect to cardiovascular and bone health.